BMS at EADV 2021
Intended for U.S. scientific audiences only.
The European Academy of Dermatology and Venereology (EADV) serves as an important exchange of scientific breakthroughs and research for physicians and patients living with serious dermatologic diseases. We look forward to presenting new research and sharing our progress advancing pathbreaking science with the hope of providing truly meaningful solutions for patients in need.
Hear from our chief medical officer of Global Drug Development, Samit Hirawat, M.D., about how we are advancing pathbreaking science with the goal of providing truly meaningful solutions for people with immune-mediated diseases.
Our Data at EADV 2021
Read more about our key data being presented at the meeting.
At EADV 2021, Bristol Myers Squibb is presenting data on an investigational compound in psoriasis as well as the company’s broader dermatology research and pipeline.
Scientific Innovations Driving Meaningful Advancements Forward
We are committed to improving the lives of patients with immune-mediated diseases, like psoriasis, psoriatic arthritis and atopic dermatitis, and remain steadfast in exploring additional potential treatment options that might provide benefit for patients where unmet need still exists. Learn more below.
Shalabh Singhal, executive director, development program lead, Rheumatology, explains how by targeting the tyrosine kinase 2 (TYK2) pathway, researchers can further our understanding of how to improve care for psoriatic disease.
Our research in Immunology and dermatology follows a science-driven pathway approach that delivers scientific innovation across key areas of focus.